Geron Corp
NASDAQ:GERN
Net Margin
Geron Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Geron Corp
NASDAQ:GERN
|
802.5m USD |
-120%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
336.1B USD |
7%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 848%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.8B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
144.7B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.8B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
129.7B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.9B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Geron Corp
Glance View
Geron Corporation, based in California, has carved a niche for itself in the biopharmaceutical industry with its pioneering focus on telomerase inhibition. This company, founded in 1990, has directed its efforts primarily towards the development of therapies for cancer treatment by leveraging its distinctive approach. Telomerase is an enzyme that often grants cancer cells the ability to replicate indefinitely, which is a critical factor in their unchecked growth. Geron's leading product candidate, imetelstat, is an innovative telomerase inhibitor, designed to disrupt this very mechanism, thereby potentially halting the proliferation of malignant cells. The company's primary business model revolves around advancing this compound through various stages of clinical trials, eyeing approval from regulatory bodies like the FDA. Revenue generation for Geron rests upon the successful progression and eventual commercialization of imetelstat. Until such advancements are fully realized, the company's financial health leans heavily on partnerships, licensing agreements, and investor funding to sustain its research activities. These collaborations often provide essential financial resources and shared expertise, necessary for moving forward within the arduous, often costly drug approval process. By staying focused on its core scientific pursuits and aligning with strategic partners, Geron plans to translate its innovative therapeutic strategies into viable market solutions, thereby capturing value from its significant investment in R&D. The commercialization of imetelstat or any pipeline success could mark transformational milestones for Geron, expanding not only its financial prospects but also potentially altering treatment paradigms in the field of oncology.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Geron Corp's most recent financial statements, the company has Net Margin of -119.5%.
You don't have any saved screeners yet